Clinical use of cyclooxygenase inhibitors impairs vitamin B-6 metabolism1-3

American Journal of Clinical Nutrition

Volumn 98, Issue 6, 2013, Pages 1440-1449

  Chang, Hsin Yueh ^a   Tang, Feng Yao ^b   Chen, Der Yuan ^c   Chih, Hui Min ^a,d   Huang, Shih Ting ^a   Cheng, Hung Dian ^a   Lan, Joung Liang ^c   Chiang, En Pei Isabel ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c Division of Allergy Immunology Rheumatology   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DICLOFENAC; MELOXICAM; NAPROXEN; NIMESULIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; SULINDAC;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG USE; ENERGY CONSUMPTION; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; RHEUMATOID ARTHRITIS; SYRIAN HAMSTER; TREATMENT DURATION; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

ANIMALS; ARTHRITIS, RHEUMATOID; CRICETINAE; CROSS-SECTIONAL STUDIES; CYCLOOXYGENASE INHIBITORS; DRUG MONITORING; FEMALE; HUMANS; KIDNEY; LIVER; MALE; MESOCRICETUS; MICE; MICE, INBRED C57BL; MIDDLE AGED; NAPROXEN; PYRAZOLES; PYRIDOXAL PHOSPHATE; SULFONAMIDES; VITAMIN B 6; VITAMIN B 6 DEFICIENCY;

EID: 84888231053     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.113.064477     Document Type: Article

References (50)

1. Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008;12:1-278, 3
2. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part 1). J Natl Cancer Inst 1998;90:1529-36
3. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008; 70:1672-7
4. Topol EJ, Falk GW. A coxib a day won't keep the doctor away. Lancet 2004;364:639-40
5. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80
6. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343:1520-8, 2 p following 1528
7. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102
8. Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998;158:1108-12
9. Andersohn F, Schade R, Suissa S, Garbe E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: A nested case-control study. Stroke 2006;37:1725-30
10. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984;310:563-72
11. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. Am J Med 1999; 106:13S-24S
12. Muscará MN, Vergnolle N, Lovren F, Triggle CR, Elliott SN, Asfaha S, Wallace JL. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol 2000;129:1423-30
13. Roubenoff R, Roubenoff RA, Selhub J, Nadeau MR, Cannon JG, Freeman LM, Dinarello CA, Rosenberg IH. Abnormal vitamin B6 status in rheumatoid cachexia. Association with spontaneous tumor necrosis factor alpha production and markers of inflammation. Arthritis Rheum 1995;38:105-9
14. Chiang EP, Bagley PJ, Selhub J, Nadeau M, Roubenoff R. Abnormal vitamin B(6) status is associated with severity of symptoms in patients with rheumatoid arthritis. Am J Med 2003;114:283-7
15. Sanderson CR, Davis RE, Bayliss CE. Serum pyridoxal in patients with rheumatoid arthritis. Ann Rheum Dis 1976;35:177-80
16. Chiang EP, Smith DE, Selhub J, Dallal G, Wang YC, Roubenoff R. Inflammation causes tissue-specific depletion of vitamin B6. Arthritis Res Ther 2005;7:R1254-R1262
17. Midttun O, Ulvik A, Ringdal P, Ebbing M, Bleie O, Schartum-Hansen H, Nilsen RM, Nyga°rd O, Ueland PM. Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation. J Nutr 2011;141:611-617
18. McKusick AB, Sherwin RW, Jones LG, Hsu JM. Urinary excretion of pyridoxine and 4-pyridoxic acid in rheumatoid arthritis. Arthritis Rheum 1964;7:636-653
19. Robinson K, Arheart K, Refsum H, Brattstrom L, Boers G, Ueland P, Rubba P, Palma-Reis R, Meleady R, Daly L, et al. Low circulating folate and vitamin B6 concentrations: Risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 1998;97:437-443
20. Smolin LA, Crenshaw TD, Kurtycz D, Benevenga NJ. Homocyst(e)ine accumulation in pigs fed diets deficient in vitamin B-6: Relationship to atherosclerosis. J Nutr 1983;113:2022-2033
21. Friso S, Girelli D, Martinelli N, Olivieri O, Lotto V, Bozzini C, Pizzolo F, Faccini G, Beltrame F, Corrocher R. Low plasma vitamin B-6 concentrations and modulation of coronary artery disease risk. Am J Clin Nutr 2004;79:992-998
22. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843
23. Wållberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999;26:2562-2571
24. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32
25. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502
26. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45
27. Chen DY, Chih HM, Lan JL, Chang HY, Chen WW, Chiang EP. Blood lipid profiles and peripheral blood mononuclear cell cholesterol metabolism gene expression in patients with and without methotrexate treatment. BMC Med 2011;9:4
28. Chang HY, Tzen JT, Lin SJ, Wu YT, Chiang EP. Long-term prednisolone treatments increase bioactive vitamin B6 synthesis in vivo. J Pharmacol Exp Ther 2011;337:102-109
29. Health Canada. ICH (International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use)/Therapeutic Products Programme. Guideline for the timing of non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals. Ottawa, Canada: Health Canada Publications, 1998. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applicdemande/guide-ld/ich/ multidisciplin/timnoncl-eng.php (cited 10 May 2013)
30. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry and reviewers estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. Fed Regist 2003 Jan 16;68:2340-2341. Available from: https://www.federalregister.gov/articles/ 2003/01/16/03-906/draft-guidance-for-industry-and-reviewers-on-estimating-the- safestarting-dose-in-clinical-trials (cited 10 May 2013)
31. Chiang EP, Wang YC, Tang FY. Folate restriction and methylenetetrahydrofolate reductase 677T polymorphism decreases adoMet synthesis via folate-dependent remethylation in human-transformed lymphoblasts. Leukemia 2007;21:651-8
32. Talwar D, Quasim T, McMillan DC, Kinsella J, Williamson C, O'Reilly DS. Optimisation and validation of a sensitive high-performance liquid chromatography assay for routine measurement of pyridoxal 5-phosphate in human plasma and red cells using pre-column semicarbazide derivatisation. J Chromatogr B Analyt Technol Biomed Life Sci 2003;792:333-433
33. Rizzo V, Montalbetti L, Valli M, Bosoni T, Scoglio E, Moratti R. Study of factors affecting the determination of total plasma 7- fluorobenzo-2-oxa-1,3- diazole-4-sulfonate (SBD)-thiol derivatives by liquid chromatography. J Chromatogr B Biomed Sci Appl 1998; 706:209-215
34. Pan WH, Wu HJ, Yeh CJ, Chuang SY, Chang HY, Yeh NH, Hsieh YT. Diet and health trends in Taiwan: comparison of two nutrition and health surveys from 1993-1996 and 2005-2008. Asia Pac J Clin Nutr 2011;20:238-250
35. Chiang EP, Selhub J, Bagley PJ, Dallal G, Roubenoff R. Pyridoxine supplementation corrects vitamin B6 deficiency but does not improve inflammation in patients with rheumatoid arthritis. Arthritis Res Ther 2005;7:R1404-R1411
36. Chiang EP, Bagley PJ, Roubenoff R, Nadeau M, Selhub J. Plasma pyridoxal 5'-phosphate concentration is correlated with functional vitamin B-6 indices in patients with rheumatoid arthritis and marginal vitamin B-6 status. J Nutr 2003;133:1056-1059
37. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94: 2504-2510
38. Harding P, Sigmon DH, Alfie ME, Huang PL, Fishman MC, Beierwaltes WH, Carretero OA. Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet. Hypertension 1997; 29:297-302
39. Kömhoff M, Grone HJ, Klein T, Seyberth HW, Nusing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function. Am J Physiol 1997;272: F460-F4608
40. Wang JL, Cheng HF, Harris RC. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 1999;34:96-101
41. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96:272-7
42. Mydlík M, Derzsiova K, Zemberova E. Metabolism of vitamin B6 and its requirement in chronic renal failure. Kidney Int Suppl 1997; 62:S56-s59
43. Ross EA, Shah GM, Reynolds RD, Sabo A, Pichon M. Vitamin B6 requirements of patients on chronic peritoneal dialysis. Kidney Int 1989;36:702-6
44. Stone WJ, Warnock LG, Wagner C. Vitamin B6 deficiency in uremia. Am J Clin Nutr 1975;28:950-7
45. Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal anti-inflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol 2006;164:881-889
46. McCormick DB. Vitamin B-6. In: Bowman BA, Russell RM, eds. Present knowledge in nutrition. 9th ed. Washington, DC: ILSI Press, 2006:269-277
47. Bowman BB, McCormick DB. Pyridoxine uptake by rat renal proximal tubular cells. J Nutr 1989;119:745-749
48. Bowman BB, McCormick DB, Smith ER. Vitamin B6 uptake by rat kidney cells and brush-border membrane vesicles. Ann N Y Acad Sci 1990;585:106-109
49. Hamm MW, Mehansho H, Henderson LM. Management of pyridoxine and pyridoxal in the isolated kidney of the rat. J Nutr 1980;110:1597-1609
50. Banks MA, Gregory JF III.Mice, hamsters and guinea pigs differ in efficiency of pyridoxine-5'-beta-D-glucoside utilization. J Nutr 1994;124:406-414